← Back to Search

Alkylating agents

Cisplatin/carboplatin plus etoposide for Small Cell Lung Cancer (REPLATINUM Trial)

Phase 3
Waitlist Available
Research Sponsored by EpicentRx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up estimated up to 12 months
Awards & highlights

REPLATINUM Trial Summary

This trial is testing a new treatment for small cell cancer that has gotten worse despite other treatments. The new treatment is a combination of a drug called RRx-001 with standard platinum-based chemotherapy.

Eligible Conditions
  • Small Cell Lung Cancer

REPLATINUM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~estimated up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and estimated up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival
Secondary outcome measures
Overall Survival
Overall response rate

REPLATINUM Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1Experimental Treatment2 Interventions
RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks Cisplatin/carboplatin plus etoposide (up to 4 cycles): Cisplatin or Carboplatin: Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks
Group II: Arm 2Active Control1 Intervention
Cisplatin/carboplatin plus etoposide (up to 4 cycles): Cisplatin or Carboplatin: Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks

Find a Location

Who is running the clinical trial?

EpicentRx, Inc.Lead Sponsor
15 Previous Clinical Trials
1,036 Total Patients Enrolled
Bryan Oronsky, MD, PhDStudy DirectorEpicentRx, Inc.
2 Previous Clinical Trials
187 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Future OncologyJournal
REPLATINUM Phase III Randomized Study: Rrx-001 + Platinum Doublet Versus Platinum Doublet in Third-line Small Cell Lung Cancer
Oronsky, Bryan, Tony R Reid, Christopher Larson, Scott Caroen, Mary Quinn, Erica Burbano, Gina Varner, et al.. 2019. “REPLATINUM Phase III Randomized Study: Rrx-001 + Platinum Doublet Versus Platinum Doublet in Third-line Small Cell Lung Cancer”. Future Oncology. Future Medicine Ltd. doi:10.2217/fon-2019-0317.
clinicaltrials.govStudy
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
2018. "RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03699956.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top